Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Return on Sales (2016 - 2025)

Sunshine Biopharma's Return on Sales history spans 10 years, with the latest figure at 0.59% for Q4 2025.

  • For Q4 2025, Return on Sales rose 14.0% year-over-year to 0.59%; the TTM value through Dec 2025 reached 0.03%, down 1.0%, while the annual FY2025 figure was 0.03%, 1.0% down from the prior year.
  • Return on Sales reached 0.59% in Q4 2025 per SBFM's latest filing, up from 0.09% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 7.84% in Q4 2021 to a low of 154.4% in Q1 2021.
  • Average Return on Sales over 5 years is 15.62%, with a median of 0.17% recorded in 2023.
  • Peak YoY movement for Return on Sales: crashed -13622bps in 2021, then skyrocketed 14432bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 7.84% in 2021, then plummeted by -176bps to 5.97% in 2022, then skyrocketed by 97bps to 0.16% in 2023, then skyrocketed by 377bps to 0.45% in 2024, then surged by 31bps to 0.59% in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Return on Sales are 0.59% (Q4 2025), 0.09% (Q3 2025), and 0.19% (Q2 2025).